The India dermatological therapeutics market size was valued at $0.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 11.4% from 2022 to 2030 and will reach $1.5 Bn in 2030 due to a number of factors, including an increased prevalence of skin diseases, and a growing awareness of skin care among the general population. The market is segmented by Type, Disease, Drug Class, and Route of Administration. The major players in the dramatological therapeutics market are Galderma India Private Limited Dr. Reddy's Laboratories, Cipla, Sun Pharmaceutical Industries, Lupin, Zydus Cadila, and others.
2. This report presents a strategic analysis of the Indian Dermatology
Therapeutics market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market value,
dynamics, segmentation, characteristics, main players, trends and insights,
growth and demand drivers, challenges & future outlook, etc. This is one of
the most comprehensive reports about the Indian Dermatology
Therapeutics market, and offers unmatched value, accuracy, and expert
insights
4. Table of Contents
4 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
1. Indian Dermatology Therapeutics Market Overview…………………………………………..…………………………………....…...........7
1.1 Background
1.2 Introduction
1.3 Market size and forecast
2. Market Growth Drivers and Restraints …………………………………………………………………….…………………………………….11
2.1 Market Growth Drivers
2.1.1 Increase in incidence of skin diseases
2.1.2 Awareness regarding skin diseases
2.1.3 Rising number of working women
2.1.4 Demand for topical dermatology drugs
2.1.5 Easy accessibility of the products
2.1.6 Government Initiatives
2.2 Market Restraints
2.2.1 Serious side effects of drugs
2.2.2 Competitors in Market
5. Table of Contents (continued)
5 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
3. Major Types of Dermatology Diseases…..…………………………………………………………………………………..………………..20
3.1 Eczema
3.2 Tinea Pedis
3.3 Urticaria/Angioedema
3.4 Atopic Dermatitis
3.5 Acne
4. Dermatology Market Segmentation………………………..…………………………………………………………………..……….….….23
4.1 By Disease Type
4.2 By Drug Class
4.3 By Route of Administration
4.4 By End Users
4.5 By Distribution Channel
5. Dermatology Major Products Market Share…………………………………………………………...…………..….......…………….….31
5.1 MarketAnalysis, Insights and Forecast - By Revenue
6. Table of Contents (continued)
6 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
6. Competitive Landscape……………………………………………………………………………………………………………….……………....33
6.1 Major Players
6.2 Products in Pipeline
7. Key Company Profiles (Company Overview, Product & Services, Strategies & Financials ) ….…………………………………..……..…...36
7.1 Sun Pharma
7.2 GlaxoSmithKline
7.3 Glenmark Pharmaceuticals
7.4 Galderma
7.5 USV Private Limited
8. Healthcare Policies and Regulatory Landscape………………………………….………………………………………………...……………..42
8.1 Regulatory Framework of Indian Dermatology Therapeutics Market
9. Factors Driving Future Growth………………………………………………………………………………………………………………….…...45
9.1 Future Opportunities
10. Conclusion……………………….…………………………………………………………………………………………………….………….…...47
10.1 Strategic Recommendations
8. 1.1 Background
8 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
▪ Skin diseases are responsible for significant morbidity worldwide, but they do not get due importance in national health planning
and policies in several countries. Although mortality due to skin diseases is low, they contribute to significant disability, and the non-
fatal burden of skin and subcutaneous diseases is more than that of cardiovascular diseases in India
▪ In India, there were 4.07 million (95% uncertainty interval 2.65–6.19 million) years lived with disability due to skin and
subcutaneous diseases in 1990, which increased to 6.26 million (95% uncertainty interval 4.12-9.35 million) in 2017.Although the
number of years lived with disability has increased by 53.7% between 1990 and 2017, the increase in age-standardised years lived
with disability rates was only 1.52%
▪ The high burden of skin and subcutaneous diseases demand that they be given due importance in the national programmes and
health policy of India
9. 1.2 Introduction
9
▪ As people age, the risk of developing skin-related disorders increases, due to factors, such as changes in the connective tissue,
reduction in the skin’s strength and elasticity, and reduction in secretions from sebaceous glands
▪ Skin conditions pose a significant threat to patient’s well-being, mental health, ability to function, and social participation
▪ In India, Dermatitis (atopic, seborrheic and contact) contributed maximum to years lived with disability (1.40Mn, 95% uncertainty
interval:0.82–2.21) followed by urticaria (1.02Mn, 95% uncertainty interval 0.06-1.44) with percentage increases of 48.9% and
45.7%, respectively
▪ Infections and infestations contributed to nearly 30 % of the total years lived with disability due to skin and subcutaneous diseases
(fungal skin diseases- 12.6%, viral skin diseases-10.0% and scabies- 10.3%)
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
10. Indian Dermatology Therapeutics Market Size US$ Mn
1.3 Market Size & Forecast
▪ Indian Dermatology Therapeutics market size stood at
around US$ xx Bn in 2021 and is projected to reach US$
xx Bn by 2030, exhibiting a CAGR of around xx% during
the forecast period
▪ The derma market has grown by approximately 4.5% per
year on an average (CAGR). The current market size of
the Dermatology segments in India is approximately $xx
Mn, growing rapidly at about xx%. In terms of revenue,
the face care products was dominating the market with
57.22% share in 2020
▪ The increasing incidence of Dermatology diseases and
increasing levels of awareness-related disease
progression, etiology, and available therapies are leading
to a high growth of Dermatology therapeutics in India
10
Key Analysis
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
xx
XX
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
12. 2.1 Market Growth Drivers
Government
Initiatives
Rise in the
incidence of skin
diseases
Awareness
regarding Skin
Diseases
Rising number
of working
women
Demand for Topical
Dermatology drugs
Easy
Accessibility of
the products
Market
Drivers
12 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
13. Market Growth Drivers
• With the rise in the aging population, Dermatology care is likely to
receive particular attention
• As people age, the risk of developing skin- related disorders
increases due to factors, such as changes in the connective tissue,
reduction in the skin's strength and elasticity, and reduction in
secretions from sebaceous glands
Sample
13
2.1.1 Rise in the incidence of skin diseases
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
14. Market Growth Drivers (continued)
▪ Increase in improvement of awareness regarding skin health in
India
Sample
14
Sample
2.1.2 Awareness regarding skin diseases
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
15. Market Growth Drivers (continued)
▪ Rising number of working women and is leading to higher demand for
personal care product
Sample
15
Sample
Sample
2.1.3 Rising number of working women
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
16. Market Growth Drivers (continued)
• Demand for topical Dermatology drugs has increased due to
increased population. It directly affects the growth of Dermatology
Market
• Drugs such as anti-inflammatory agents, anti-infective, local
anaesthetics, cleansers, and emollients to treat acne
Sample
16
Sample
2.1.4 Demand for Topical Dermatology drugs
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
17. Market Growth Drivers (continued)
• Easy accessibility of the products through company websites
and online channels, and doorstep delivery are driving the
market
Sample
Sample
17
Sample
2.1.5 Easy accessibility of the products
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
18. Market Growth Drivers (continued)
▪ The initiatives taken by the government are expected to
contribute to the growth of the dermatology market in
India
▪ For example, PMJY, is funded tertiary health coverage
scheme, which provides cashless surgical treatments for
various ailments, including Dermatology problems
Sample
18
Sample
2.1.6 Government Initiatives
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
19. 2.2.1 Serious side effects
2.2 Market Restraints
▪ Serious side effects of certain classes of
therapeutic drugs are expected to restrain the
market growth in the near future
▪ Due to the presence of numerous globally
operating companies, the Indian skincare derma
cosmetics market is fragmented, which is
prompting the players to launch new products
Sample Sample
19
2.2.2 Competitors in market
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
21. 3. Major Dermatology Diseases
Eczema Tinea Pedis
About 10% of the total
population may be affected by
dermatophyte infections of the
toe clefts
The condition is more common
in adult males than in females
In India, at least one in five
children suffer from eczema,
also known as atopic
dermatitis. “Since the
underlying causes are
incompletely known, we
undertook a study to identify
correlates of the disease”
Urticaria ⁄Angioedema
Chronic urticaria is a relatively common
condition in India and most cases have no
specific allergic trigger and remain
idiopathic
Autoimmune causes have been found to
be associated with up to 30- 40% cases
It is important to look for physical
urticarias such as pressure urticaria in
chronic cases
3.1 3.2 3.3
21 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
22. Major Dermatology Diseases
Atopic Dermatitis
Atopic Dermatitis (AD) is hereditary and
the most common type of eczema. AD
almost always starts in infancy or before
age 5
Acne
In India, about 12 percent between 20 to 29
years of age had acne problems.
Excess oil production, pores becoming
clogged by sticky skin cells, bacteria and
inflammation directly contributed to acne
problems
3.5
22
3.4
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
24. Snapshot of Dermatology Therapeutics Market Segmentation
By Disease Type
By Drug Class
By Route Of Administration
By End Users
Dermatology
Market
Segmentation
By Distribution Type
24 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
25. Snapshot of Dermatology Therapeutics Market Segmentation
DISEASE TYPE DRUG CLASS
ROUTE OF
ADMINISTRA
TION END USERS DISTRIBUTION CHANNEL
• Acne
• Dermatitis
• Psoriasis
• Skin
Cancer
• Alopecia
• Rosacea
• Anti-infectives
• Corticosteroid
s
• Calcineurin
inhibitors
• Retinoids
• Antirheumatic
• Oral
• Topical
• Parenteral
Administratio
n
• Home Care
• Hospital
• Dermatolog
y
Clinics
• Pharmacy
Store
• Retail Store
• Online
25 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
26. ▪ Approximately 80 percent of Indian are affected by acne
between the onset of puberty and 30 years of age. By the
end of 2026, the number of people affected by acne in
India is estimated to reach 23 million at a compound
annual growth rate (compound average growth rate) of
0.5 percent.
▪ In India, the incidence of melanoma of the skin in the
North region is 1.62 for males and 1.21 for females for
every 1,00,000 people. The overall incidence of
nonmelanoma skin cancer is the highest in the Northeast
region, going as high as 5.14 for men and 3.98 for women
for every 1,00,000 people.
▪ Content
4.1 Market Segmentation: By Disease Type
Indian Dermatology Therapeutic Market Share by Disease type
2022
Key Insights
Acn
e
26
Eczem
a
Atopic
Dermatiti
s
Skin
Cancer
Tinea
Pedis
SAMPLE
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
27. ▪ The biologics segment is expanding at a large scale
during the forecast period owing to the increasing
regulatory approval of biologics.
▪ Anti-infectives are medicines that work to prevent or treat
infections, they include antibacterials, antivirals,
antifungals and antiparasitic medications.
▪ Topical corticosteroids are effective in a number of
dermatoses. Dermatotherapy has always been a
combination of art and science.
Sample
4.2 Market Segmentation: By Drug Type
Indian Dermatology Therapeutics Market Share by Drug Type
2022
27
Anti-infectives Corticosteroids Calceneurin
Inhibitors
Retinoids Antirhematic
SAMPLE
Key Insights
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
28. 4.3 Market Segmentation: Route of Administration
Topical
Oral
Parenteral
administration
Topical Oral Parenteral
administration
▪ In Indian dermatology therapeutics market, the topical
segment held a large share of the market owing to the
rise in the demand for topical Dermatology drugs such as
anti-inflammatory agents, anti-infective, local anesthetics,
cleansers, and emollients to treat acne.
28
Key Insights
Indian Dermatology Therapeutic Market Share by Route of
Administration, 2022
SAMPLE
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
29. 4.4 Market Segmentation: By End Users
▪ Hospitals provide medical, diagnostic, and treatment
services to inpatients and some outpatient dermatology
services, which is holding largest share of the
dermatology market
▪ Large number patients are being treated at home, which
is holding market share following hospitals in dermatology
market
Hospitals Homecare DermatologyClinics
29
SAMPLE
Key Insights
Indian Dermatology Therapeutic Market Share by End User,
2022
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
30. 4.5 Market Segmentation: By Distribution Channels
▪ It is expected that the pharmacy and retail store category will
lead throughout the forecast period.
▪ This is due to the availability of a broad range of over-the-
counter derma products, which are available in the
pharmacy and retail stores.
▪ However, with the increasing trend toward online shopping
and due to Covid-19 impact, people are preferring to make
an online purchase and due to this online category is also
witnessing faster growth in the dermatology market
30
Pharmacy Store Retail Store Online
SAMPLE
Key Insights
Indian Dermatology Therapeutic Market Share by Distribution
Channel, 2022
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
32. 44
Top Brands in Dermatology Therapeutics Market
5.1 Major Dermatology Products Market Share
Key Insights
Indian Dermatology Therapeutics Major
Products Market Share
Brand 1 Brand 2 Brand3 Brand 4
SAMPLE
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
34. 6.1 Major Players Revenue (Current and Forecast)
34
2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Sun Pharma $XX $XX $XX $XX $XX $XX $XX $XX $XX $XX
GlaxoSmithKline
$XX $XX $XX $XX $XX $XX $XX $XX $XX $XX
Glenmark
Pharmaceuticals
$XX $XX $XX $XX $XX $XX $XX $XX $XX $XX
Galderma India Private
Limited
$XX $XX $XX $XX $XX $XX $XX $XX $XX $XX
USV Private Limited. $XX $XX $XX $XX $XX $XX $XX $XX $XX $XX
Revenue of Major Dermatology Market Players ($Bn)
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
35. 48
6.2 Products in Pipeline
▪ Lipidor AB has penned an agreement with Cadila Pharmaceuticals
to conduct a Phase III study for Lipidor’s drug candidate AKP-02.
AKP-02 is an antipsoriasis medicine that combines the active
substances calcipotriol and betamethasone with Lipidor’s spray-
based AKVANO technology
Content
Sample
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
37. 7.1 Sun Pharma
Company Profile
Company Name: Sun Pharma
Year of Establishment: 1983
Headquarter: India
Revenue: $4.5 Bn
Website www.sunpharma.com
Sample
37 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
38. Sample
Company Name: GlaxoSmithKline
Year of Establishment: 2000
Headquarter: United Kingdom
Revenue: $xx Bn
Website: www.gsk.com
Company Profile
38
7.2 GlaxoSmithKline
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
39. Sample
Company Name: Glenmark Pharmaceuticals
Year of Establishment: 1977
Headquarter: Mumbai, India
Revenue: $xx Bn
Website: www.glenmarkpharma.com
Company Profile
39
7.3 Glenmark Pharmaceuticals
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
40. 7.4 Galderma India Private Limited
Company Profile
Company Name: Galderma India Private
Limited
Year of Establishment: 1981
Headquarter: SA Lausanne, Switzerland
Revenue: $3.4 Bn
Website: www.galderma.com
Sample
40 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
41. Sample
Company Name: USV Private
Limited
Year of Establishment: 1959
Headquarter: Mumbai, India
Revenue: $2.3 Bn
Website: www.usvindia.com
Company Profile
41
7.5 USV Private Limited
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
43. 8.1 Regulatory Framework of India Dermatology Therapeutics Market
The Indian Association of Dermatologists,
Venereologists and Leprologists (IADVL),
the largest representing official society of
Indian Dermatologists was established in its
present form on 28th January, 1973
The journey that culminated in the
formation of IADVL as we know it today
took its first flight in 1947 when Dr. UB
Narayan Rao, conceived the idea to create
an association of Dermatologists and
Venereologists
IADVL is the national association of Indian
medical specialists who manage patients
with skin disorders, sexually transmitted
infections (STIs) or leprosy. The association
works for the betterment of the specialty by
holding academic meetings, printing a
journal (print version & online)
A framework regarding rules was approved on
July 26, 1948 and the association started its
work on establishing local branches in other
states. IADVL also happens to be the world’s
2nd largest Association of Dermatologists
behind the American Academy of Dermatology
43 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
44. Regulatory Framework of India Dermatology Therapeutic Market
• The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) organization is
ever committed to serving the public in the domains of dermatology. In lieu of this, IADVL observes
several days of clinical significance including Leprosy day, Vitiligo day, World Skin Health Day to
name a few
• IADVL has a wing dedicated to Community outreach programs which not only help in taking
quality skin care to the rural remote areas but also promote awareness on skin hygiene, equipping
the local medical personnel to manage the common skin conditions and to refer the complicated
cases to higher referral centers
• Indian Dermatology Online Journal (IDOJ) is a bimonthly open access print journal of Indian
Association of Dermatologists, Venereologists and Leprologists (IADVL)
44 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
46. 9. Future Opportunities
.
The prime strategically activities
within the market are initiated by
the key players which incorporate
product developments, mergers,
and acquisitions, partnerships, etc.
The new vendors within the Dermatology
Diagnostic Devices and Therapeutics market
face powerful competition from established
international vendors as they struggle with
technological innovations, dependability, and
quality problems
The Indian Journal of Dermatology
has always played a progressive
role of acting as a medium for the
ever- changing developments of
scientific research in dermatology in
this part of the world
46
Future
Opportunities
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
48. 10.1 Strategic Recommendations
Dermatology in the new
millennium must focus on the
needs, hopes, and
satisfaction of those who
consider themselves to have
skin liaments. Governments
can change this by declaring
some unidentified needs to be
important and thus fundable,
while others are deemed
unimportant
The importance of skin to the
individual will not diminish,
and funding agencies should
recognize this. The costs of
treating skin diseases will
always be an issue, and the
case for treating skin
diseases will have to be
made in a competitive world
filled with many life-
threatening diseases
Dermatologists may
themselves opt out of treating
conditions which governance
deems important. An example
would be all breaks in surface
continuity of the skin which
other professions might wish
to take over as leg ulcers, the
diabetic foot ulcer, the
pressure sore, or burns
48 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
50. Research Methodology
A Sample Report on Indian Dermatology Therapeutics Market I Confidential
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ The currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion
51. 51 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
Analysis Methodology
Our Analysis Methodology involves three critical stages:
Primary
Interviews
Secondary
Data
Market Trends
Market Sizing
& Analysis
Data Triangulation
& Validation
Analysis &
Interpretation
Insights
Presentation
& Reporting
Data Collection
Market Data Analysis &
Statistical Model
Interpretation and
Presentation
52. 52 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
Bottom-up Analysis
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary
Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary
Interview
Final
Summary
Data Triangulation and Data Validation
53. Key Benefit for Stakeholders from this report
The study provides an in-depth analysis of the Indian dermatology therapeutics market with current trends and future estimations
to elucidate the imminent investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2021 to 2030 is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors
53 A Sample Report on Indian Dermatology Therapeutics Market I Confidential
54. 2021
2022-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (5 working days) with
purchase. We will provide you with data that is
currently not a part of our scope as a part of
customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period
55. The report is prepared
using a proven
methodology and
insightful research
Reliable
The data is prepared by
a team of highly qualified
& experienced research
analysts & vetted by our
local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything you
would need to know
about the market
including market size,
competitive analysis &
much more
Comprehensive
You do not have to be a
market expert to
understand what really is
happening on the market
and how it works
Easy to read
What kind of Data is Presented
in this Report?
This report presents data, which is:
www.insights10.com
57. www.insights10.com
A large database of over 30,000 syndicated market
research reports in pharmaceuticals and
healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Lifesciences Market
Research Reports you
can trust
58. Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
Get Insights to take
informed Business
Decisions
www.insights10.com
59. Market Research Reports
across various domains of healthcare
Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Pharmaceuticals
(Diseases & Drugs)
Digital
Health
Medical
Devices
61. Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis
www.insights10.com
62. Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players
www.insights10.com
63. Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions
64. Mukesh is an engineering graduate
with an MBA in Marketing. He is a
seasoned healthcare market
research & marketing professional
with a progressive experience of over
20 years in Life Sciences, Pharma
and Medical Device sectors . With an
in-depth understanding of primary
research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare
& completed several research
projects across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Dhruv Joshi is an engineer and has done
Masters in Hospital Administration with
over 4 years of experience in the
healthcare and life science industry. He
has gained proficiency in market
research, market assessment, and
developing insights from it. He has
worked on various consulting projects
across different geographies including
Asia, Europe, US, MENA. He has been
aligned in working for sector reports of
various geographies along with market
sizing and forecasting.
Dr. Purav Gandhi
Founder & CEO
Mukesh Nayak
Head - Marketing
Ritu Baliya
Engagement Manager
Dhruv Joshi
Consultant
Project Leadership Team
65. 7 years of experience working with leading organizations in pharma, MedTech
and healthcare domain. Some of our recent clients are mentioned below
… and many more